Although osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is the standard first-line treatment for metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutations (1–4), the development of acquired resistance inevitably limits its long-term efficacy (1). This evidence concerns the gene EGFR and non-small cell lung carcinoma.